Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. September 2016 11:00 ET | Quelle: Cellceutix

Cellceutix Announces Appointment of Vice President for Regulatory Affairs

BEVERLY, MA--(Marketwired - September 16, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
13. September 2016 08:30 ET | Quelle: Cellceutix

Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones

BEVERLY, MA--(Marketwired - September 13, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
07. September 2016 07:00 ET | Quelle: Cellceutix

Cellceutix Corporation to Present at Upcoming Conferences

BEVERLY, MA--(Marketwired - September 07, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
30. August 2016 14:07 ET | Quelle: Cellceutix

Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran

BEVERLY, MA--(Marketwired - August 30, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
03. August 2016 09:30 ET | Quelle: Cellceutix

Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data

BEVERLY, MA--(Marketwired - August 03, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
21. Juli 2016 07:00 ET | Quelle: Cellceutix

Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis

BEVERLY, MA --(Marketwired - July 21, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
18. Juli 2016 10:00 ET | Quelle: Cellceutix

Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis

BEVERLY, MA--(Marketwired - July 18, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
07. Juli 2016 08:30 ET | Quelle: Cellceutix

Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis

BEVERLY, MA--(Marketwired - July 07, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
30. Juni 2016 13:00 ET | Quelle: Cellceutix

Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer

BEVERLY, MA--(Marketwired - June 30, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
15. Juni 2016 11:45 ET | Quelle: Cellceutix

Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis

BEVERLY, MA--(Marketwired - June 15, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...

Nächste Seite